Disease · HP_0003124

Hypercholesterolemia

6 sourcesdiseases-2026-09-18-0.1.0

Cite this record

ConductScience Library. Hypercholesterolemia. Diseases, record HP_0003124. Release diseases-2026-09-18-0.1.0, 18 Sept 2026. https://conductscience.org/library/diseases/HP_0003124

On this page

Disease

Names and IDs as Open Targets gives them. Its IDs in MeSH, Orphanet, the Disease Ontology and the NCI Thesaurus are those Open Targets states for it.

Name: Hypercholesterolemia; Open Targets
Open Targets ID: HP_0003124; Open Targets
Other names: Elevated serum cholesterol, Elevated total cholesterol, Increased total cholesterol; Open Targets
NCI Thesaurus: C37967; NCI Thesaurus
Highest stage of its drugs: Approval, for 27 of its 92 drugs, from DailyMed, EMA Human Drugs, FDA and PMDA; Open Targets

Drugs92

The drugs Open Targets' clinical reports study for the disease, the highest stage first, then the most trial reports. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.

Drug	ChEMBL ID	Type	Open Targets' stage	Stage reported by	Reports	Of them trials	Trials shown here	Source
EZETIMIBE	CHEMBL1138	Small molecule	Approval	DailyMed, EMA Human Drugs and PMDA	108	86	85	Drugs and targets
ATORVASTATIN	CHEMBL1487	Small molecule	Approval	PMDA	69	67	67	Drugs and targets
ROSUVASTATIN	CHEMBL1496	Small molecule	Approval	PMDA	48	47	47	Drugs and targets
SIMVASTATIN	CHEMBL1064	Small molecule	Approval	DailyMed	161	46	45	Drugs and targets
ALIROCUMAB	CHEMBL2109540	Antibody	Approval	PMDA	22	21	21	Drugs and targets
EVOLOCUMAB	CHEMBL2364655	Antibody	Approval	EMA Human Drugs and PMDA	19	17	17	Drugs and targets
BEMPEDOIC ACID	CHEMBL3545313	Small molecule	Approval	EMA Human Drugs	16	14	14	Drugs and targets
PITAVASTATIN	CHEMBL1201753	Small molecule	Approval	PMDA	11	10	10	Drugs and targets
NIACIN	CHEMBL573	Small molecule	Approval	DailyMed	14	8	7	Drugs and targets
FENOFIBRATE	CHEMBL672	Small molecule	Approval	DailyMed	9	5	5	Drugs and targets

1 to 10 of 92

See all 92 drugs

Targets43

The targets ChEMBL's mechanism records give for the disease's drugs, through Open Targets, the most drugs first. A mechanism record says what a drug acts on, not that the target causes the disease.

Target	Protein	Its drugs that act on it	Mechanisms	Highest stage of those drugs	Gene in Genes	Source
HMGCR	3-hydroxy-3-methylglutaryl-coenzyme A reductase	12	HMG-CoA reductase inhibitor	Approval	https://conductscience.org/library/genes/3156	Drugs and targets
PCSK9	PCSK9 mRNA	9	PCSK9 mRNA RNAi inhibitor; PCSK9 mRNA rnai inhibitor; Subtilisin/kexin type 9 inhibitor	Approval	https://conductscience.org/library/genes/255738	Drugs and targets
AGTR1	Type-1 angiotensin II receptor	5	Type-1 angiotensin II receptor antagonist	Phase 3	https://conductscience.org/library/genes/185	Drugs and targets
CETP	Cholesteryl ester transfer protein	4	Cholesteryl ester transfer protein inhibitor	Phase 3	https://conductscience.org/library/genes/1071	Drugs and targets
PPARA	Peroxisome proliferator-activated receptor alpha	4	Peroxisome proliferator-activated receptor alpha agonist	Approval	https://conductscience.org/library/genes/5465	Drugs and targets
THRB	Thyroid hormone receptor beta	3	Thyroid hormone receptor beta-1 agonist	Phase 2	https://conductscience.org/library/genes/7068	Drugs and targets
APOB	Apo-B 100 mRNA	2	Apo-B 100 mRNA antisense inhibitor	Phase 3	https://conductscience.org/library/genes/338	Drugs and targets
CACNA1C	Voltage-gated L-type calcium channel	2	Voltage-gated L-type calcium channel blocker	Approval	https://conductscience.org/library/genes/775	Drugs and targets
CACNA1D	Voltage-gated L-type calcium channel	2	Voltage-gated L-type calcium channel blocker	Approval	https://conductscience.org/library/genes/776	Drugs and targets
CACNA1F	Voltage-gated L-type calcium channel	2	Voltage-gated L-type calcium channel blocker	Approval	https://conductscience.org/library/genes/778	Drugs and targets

1 to 10 of 43

See all 43 targets

Trials293

Trials an Open Targets clinical report links to the disease, posted results first, then the largest. A trial is shown when the release's checks confirm its link to the disease and Drugs and targets shows its link to one of the disease's drugs. 7 more are not shown, since the checks do not confirm them.

Trial	Title	Phase	Participants	Results first posted	Conditions	Drugs	Linked by	Source
NCT00909389	Post-marketing Surveillance of the Safety, Tolerability and Efficacy of Vytorin (Ezetimibe + Simvastatin) Tablet Among Filipino Patients (Study P05647)		4,748	2011-10-04	Hypercholesterolemia	EZETIMIBE, SIMVASTATIN	Its record names the disease	ClinicalTrials.gov
NCT00704535	Evaluation of the Safety, Tolerability and Efficacy of Ezetimibe on a Select Population of Filipinos With Hypercholesterolemia (Study P04748)(COMPLETED)		4,105	2009-07-14	Primary Hypercholesterolemia, Homozygous Familial Hypercholesterolemia	EZETIMIBE	Its record names the disease	ClinicalTrials.gov
NCT00479882	MK-0524B Lipid Study (MK-0524B-063)	Phase 3	2,414	2016-04-01	Primary Hypercholesterolemia, Mixed Dyslipidemia	LAROPIPRANT	Open Targets' reading of its record	ClinicalTrials.gov
NCT01507831	Long-term Safety and Tolerability of Alirocumab (SAR236553/REGN727) Versus Placebo on Top of Lipid-Modifying Therapy in High Cardiovascular Risk Patients With Hypercholesterolemia (ODYSSEY Long Term)	Phase 3	2,341	2015-12-22	Hypercholesterolemia	ALIROCUMAB	Its record names the disease	ClinicalTrials.gov
NCT01154036	MK0653C in High Cardiovascular Risk Patients With High Cholesterol (Switch Study)(MK-0653C-162)	Phase 3	1,547	2014-02-12	Hypercholesterolemia	ATORVASTATIN, EZETIMIBE	Its record names the disease	ClinicalTrials.gov
NCT01439880	Open Label Study of Long Term Evaluation Against LDL-C Trial	Phase 2	1,324	2019-07-10	Hypercholesterolemia	EVOLOCUMAB	Its record names the disease	ClinicalTrials.gov
NCT00535405	A Study to Assess the Cholesterol Lowering Effect of Ezetimibe/Simvastatin Combination Tablet Compared to Another Cholesterol Lowering Drug in Elderly Patients With High Cholesterol at High or Moderately High Risk for Coronary Heart Disease (0653A-128)	Phase 3	1,289	2010-05-25	Hypercholesterolemia	EZETIMIBE, SIMVASTATIN	Its record names the disease	ClinicalTrials.gov
NCT00479388	Study of Extended Release Niacin/Laropiprant on Lipids (0524A-067)	Phase 3	1,216	2009-07-31	Primary Hypercholesterolemia, Mixed Dyslipidemia	LAROPIPRANT, NIACIN	Open Targets' reading of its record	ClinicalTrials.gov
NCT04964544	Technology-Assisted Cholesterol Trial in Consumers (TACTiC)	Phase 3	1,196	2024-10-30	High Cholesterol	ROSUVASTATIN CALCIUM	Its record names the disease	ClinicalTrials.gov
NCT01274559	Efficacy and Safety of Extended Release (ER) Niacin/Laropiprant When Added to Ongoing Lipid-Modifying Therapy in Patients With High Cholesterol or Abnormal Lipid Levels (MK-0524A-133)	Phase 3	1,173	2014-03-14	Primary Hypercholesterolemia, Mixed Dyslipidemia	NIACIN	Open Targets' reading of its record	ClinicalTrials.gov

1 to 10 of 293

See all 293 trials

Comparisons in its trials57

Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.

Comparison	Group 1, with the outcome	Group 2, with the outcome	Participants	Trial	Source
Alirocumab 150 mg Q2W vs Placebo Q2W: serious adverse events	290 of 1,550	154 of 788	2,338	NCT01507831	Trial comparisons
Extended-release Niacin/Laropiprant vs Placebo: serious adverse events	23 of 572	16 of 572	1,144	NCT01274559	Trial comparisons
Atorvastatin Administration Group vs Rosuvastatin Administration Group: serious adverse events	14 of 506	19 of 516	1,022	NCT01544309	Trial comparisons
Alirocumab 75/Up to 150 mg Q2W vs Ezetimibe 10 mg: serious adverse events	124 of 479	60 of 241	720	NCT01644188	Trial comparisons
MK0524A 2 g vs Placebo: serious adverse events	3 of 321	2 of 323	644	NCT00536510	Trial comparisons
Ezetimibe 10 mg vs Alirocumab 75 mg Q2W/up150 mg Q2W: deaths from any cause	3 of 206	2 of 406	612	NCT02715726	Trial comparisons
Ezetimibe 10 mg vs Alirocumab 75 mg Q2W/up150 mg Q2W: serious adverse events	23 of 206	41 of 406	612	NCT02715726	Trial comparisons
Pitavastatin 2 mg QD vs Pitavastatin 4 mg QD: serious adverse events	51 of 449	7 of 90	539	NCT00330876	Trial comparisons
Alirocumab 75 mg Q2W/Up to 150 mg Q2W vs Placebo Q2W: deaths from any cause	0 of 344	1 of 170	514	NCT02585778	Trial comparisons
Alirocumab 75 mg Q2W/Up to 150 mg Q2W vs Placebo Q2W: serious adverse events	31 of 344	16 of 170	514	NCT02585778	Trial comparisons

1 to 10 of 57

See all 57 comparisons in its trials

Papers from its trials195

The papers the trials shown here list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.

PMID	Listed as	Trials listing it	Source
37722882	RESULT	1	PubMed
36908150	RESULT	1	PubMed
32230818	RESULT	1	PubMed
28624096	RESULT	1	PubMed
27956003	RESULT	1	PubMed
27625344	RESULT	1	PubMed
27452202	RESULT	1	PubMed
27287699	RESULT	1	PubMed
26924051	RESULT	1	PubMed
26444323	RESULT	1	PubMed

1 to 10 of 195

See all 195 papers from its trials

Data dates

The date of each source this release read.

Open Targets: 2026-09-18; Open Targets
Drug links and their checks, from Drugs and targets: 2026-09-18; Drugs and targets
ClinicalTrials.gov, from Trials: 2026-11-12; Trials
Comparisons, from Trial comparisons: 2026-03-23; Trial comparisons
PubMed, for the checks: 2026-11-06; PubMed
MeSH, for the checks: 2026-11-10; MeSH

Sources 6

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ChEMBL, through Open TargetsCC BY-SA 3.0
ClinicalTrials.govNo license stated
NLM's MeSHNLM's terms
Open TargetsCC0 1.0
PubMedNLM's terms

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
ClinicalTrials.govnone stated
NLM's MeSHNLM's
Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
PubMedNLM's terms

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this disease from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/diseases/v1/HP_0003124

GET https://conductscience.org/api/diseases/v1/HP_0003124/drugs?page=2

API reference For AI assistants